Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice

Autoimmunity

Volumn 48, Issue 7, 2015, Pages 471-487

  Yung, Susan ^a   Zhang, Qing ^a   Chau, Mel K M ^a   Chan, Tak Mao ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cyclophosphamide; lupus nephritis; mesangial cells; methylprednisolone; mycophenolate mofetil; renal fibrosis

Indexed keywords

COLLAGEN TYPE 1; CREATININE; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; FIBRONECTIN; HEMOGLOBIN; INTERLEUKIN 6; MATRIX PROTEIN; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PROTEIN KINASE C ALPHA; TRANSFORMING GROWTH FACTOR BETA1; UREA; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN-6, MOUSE; NONSTEROID ANTIINFLAMMATORY AGENT;

ALBUMIN TO CREATININE RATIO; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CREATININE URINE LEVEL; CYTOKINE RELEASE; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; FIBROGENESIS; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS BASEMENT MEMBRANE; HEMOGLOBIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNE COMPLEX DEPOSITION; IN VITRO STUDY; INFLAMMATORY CELL; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MESANGIUM CELL; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PROTEINURIA; SURVIVAL; SURVIVAL RATE; T LYMPHOCYTE; TREATMENT DURATION; UROGENITAL SYSTEM PARAMETERS; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; KIDNEY; KIDNEY FUNCTION TEST; LUPUS NEPHRITIS; MALE; MORTALITY; PATHOLOGY; SURVIVAL ANALYSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; FIBRONECTINS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; KIDNEY; KIDNEY FUNCTION TESTS; LUPUS NEPHRITIS; MALE; MESANGIAL CELLS; METHYLPREDNISOLONE; MICE; MYCOPHENOLIC ACID; PROTEIN KINASE C-ALPHA; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84946562046     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916934.2015.1054027     Document Type: Article

References (57)

1. Cameron, J. S. 1999. Lupus nephritis. J. Am. Soc. Nephrol. 10: 413-424.
2. Austin III, H. A., L. R. Muenz, K. M. Joyce, et al. 1984. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int. 25: 689-695.
3. Boumpas, D. T., H. A. Austin III, E. M. Vaughn, et al. 1992. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 340: 741-745.
4. Chan, T. M., F. K. Li, C. S. Tang, et al. 2000. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 343: 1156-1162.
5. Illei, G. G., H. A. Austin, M. Crane, et al. 2001. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 135: 248-257.
6. Contreras, G., V. Pardo, B. Leclercq, et al. 2004. Sequential therapies for proliferative lupus nephritis. N. Engl. J. Med. 350: 971-980.
7. Appel, G. B., G. Contreras, M. A. Dooley, et al. 2009. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20: 1103-1112.
8. Chan, T. M., K. C. Tse, C. S. Tang, et al. 2005. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16: 1076-1084.
9. Baer, P. C., S. Gauer, I. A. Hauser, et al. 2000. Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro. Nephrol. Dial. Transplant. 15: 184-190.
10. Huang, Y., Z. Liu, H. Huang, et al. 2005. Effects of mycophenolic acid on endothelial cells. Int. Immunopharmacol. 5: 1029-1039.
11. Heinz, C., T. Hudde, K. Heise, and K. P. Steuhl. 2002. Antiproliferative effect of mycophenolate mofetil on cultured human Tenon fibroblasts. Graefes Arch. Clin. Exp. Ophthalmol. 240: 408-414.
12. Hauser, I. A., L. Renders, H. H. Radeke, et al. 1999. Mycophenolate mofetil inhibits rat and human mesangial cell proliferation by guanosine depletion. Nephrol. Dial. Transplant. 14: 58-63.
13. Yung, S., Q. Zhang, C. Z. Zhang, et al. 2009. Anti-DNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. Arthritis Rheum. 60: 2071-2082.
14. Dubus, I., B. Vendrely, I. Christophe, et al. 2002. Mycophenolic acid antagonizes the activation of cultured human mesangial cells. Kidney Int. 62: 857-867.
15. Yung, S., C. Y. Ng, S. K. Ho, et al. 2015. Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF-beta1 and collagen synthesis. J. Autoimmun. 58: 111-122.
16. Badid, C., M. Vincent, B. McGregor, et al. 2000. Mycophenolate mofetil reduces myofibroblast infiltration and collagen III deposition in rat remnant kidney. Kidney Int. 58: 51-61.
17. Yap, D. Y., C. S. Tang, M. K. Ma, et al. 2012. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol. Dial. Transplant. 27: 3248-3254.
18. Lui, S. L., R. Tsang, D. Wong, et al. 2002. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupusprone MRL/lpr mice. Lupus. 11: 411-418.
19. Hahn, B. H., L. Knotts, M. Ng, and T. R. Hamilton. 1975. Influence of cyclophosphamide and other immunosuppressive drugs on immune disorders and neoplasia in NZB/NZW mice. Arthritis Rheum. 18: 145-152.
20. Kiberd, B. A., and I. D. Young. 1994. Modulation of glomerular structure and function in murine lupus nephritis by methylprednisolone and cyclophosphamide. J. Lab. Clin. Med. 124: 496-506.
21. Moreth, K., R. Brodbeck, A. Babelova, et al. 2010. The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J. Clin. Invest. 120: 4251-4272.
22. Janssen, U., S. G. Riley, A. Vassiliadou, et al. 2003. Hypertension superimposed on type II diabetes in Goto Kakizaki rats induces progressive nephropathy. Kidney Int. 63: 2162-2170.
23. Xia, Y., L. C. Herlitz, S. Gindea, et al. 2015. Deficiency of fibroblast growth factor-inducible 14 (Fn14) preserves the filtration barrier and ameliorates lupus nephritis. J. Am. Soc. Nephrol. 26: 1053-1070.
24. Yung, S., K. F. Cheung, Q. Zhang, and T. M. Chan. 2010. AntidsDNA antibodies bind to mesangial annexin II in lupus nephritis. J. Am. Soc. Nephrol. 21: 1912-1927.
25. Herber, D., T. P. Brown, S. Liang, et al. 2007. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J. Immunol. 178: 3822-3830.
26. Chan, T. M., J. K. Leung, S. K. Ho, and S. Yung. 2002. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 13: 1219-1229.
27. Yung, S., R. C. Tsang, J. K. Leung, and T. M. Chan. 2006. Increased mesangial cell hyaluronan expression in lupus nephritis is mediated by anti-DNA antibody-induced IL-1beta. Kidney Int. 69: 272-280.
28. Sollinger, H. W., M. H. Deierhoi, F. O. Belzer, et al. 1992. RS-61443 - a phase I clinical trial and pilot rescue study. Transplantation 53: 428-432.
29. Haubitz, M., F. Bohnenstengel, R. Brunkhorst, et al. 2002. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int. 61: 1495-1501.
30. Border, W. A., and N. A. Noble. 1997. TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 51: 1388-1396.
31. Chan, T. M. 2012. Recent progress in the treatment of proliferative lupus nephritis. Am. J. Med. 125: 642-648.
32. Isenberg, D., G. B. Appel, G. Contreras, et al. 2010. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology 49: 128-140.
33. Daikh, D. I., and D. Wofsy. 2001. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J. Immunol. 166: 2913-2916.
34. Schiffer, L., J. Sinha, X. Wang, et al. 2003. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition. J. Immunol. 171: 489-497.
35. Van Bruggen, M. C., B. Walgreen, T. P. Rijke, and J. H. Berden. 1998. Attenuation of murine lupus nephritis by mycophenolate mofetil. J. Am. Soc. Nephrol. 9: 1407-1415.
36. Corna, D., M. Morigi, D. Facchinetti, et al. 1997. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int. 51: 1583-1589.
37. Ginzler, E. M., M. A. Dooley, C. Aranow, et al. 2005. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353: 2219-2228.
38. Gharaee-Kermani, M., R. Wiggins, F. Wolber, et al. 1996. Fibronectin is the major fibroblast chemoattractant in rabbit antiglomerular basement membrane disease. Am. J. Pathol. 148: 961-967.
39. Eddy, A. A. 1996. Molecular insights into renal interstitial fibrosis. J. Am. Soc. Nephrol. 7: 2495-2508.
40. Nath, K. A. 1992. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am. J. Kidney Dis. 20: 1-17.
41. Nath, K. A. 1998. The tubulointerstitium in progressive renal disease. Kidney Int. 54: 992-994.
42. Bilyy, R. O., T. Shkandina, A. Tomin, et al. 2012. Macrophages discriminate glycosylation patterns of apoptotic cell-derived microparticles. J. Biol. Chem. 287: 496-503.
43. Fraser, D. A., A. K. Laust, E. L. Nelson, and A. J. Tenner. 2009. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. J. Immunol. 183: 6175-6185.
44. Menke, J., W. A. Rabacal, K. T. Byrne, et al. 2009. Circulating CSF-1 promotes monocyte and macrophage phenotypes that enhance lupus nephritis. J. Am. Soc. Nephrol. 20: 2581-2592.
45. Lee, S., S. Huen, H. Nishio, et al. 2011. Distinct macrophage phenotypes contribute to kidney injury and repair. J. Am. Soc. Nephrol. 22: 317-326.
46. Brown, L. F., D. Dubin, L. Lavigne, et al. 1993. Macrophages and fibroblasts express embryonic fibronectins during cutaneous wound healing. Am. J. Pathol. 142: 793-801.
47. Barnes, J. L., E. S. Torres, R. J. Mitchell, and J. H. Peters. 1995. Expression of alternatively spliced fibronectin variants during remodeling in proliferative glomerulonephritis. Am. J. Pathol. 147: 1361-1371.
48. Yung, S., R. C. Tsang, Y. Sun, et al. 2005. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J. Am. Soc. Nephrol. 16: 3281-3294.
49. Nishimoto, N., and T. Kishimoto. 2006. Interleukin 6: from bench to bedside. Nat. Clin. Pract. Rheumatol. 2: 619-626.
50. Nagafuchi, H., N. Suzuki, Y. Mizushima, and T. Sakane. 1993. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J. Immunol. 151: 6525-6534.
51. Takeno, M., H. Nagafuchi, S. Kaneko, et al. 1997. Autoreactive T cell clones from patients with systemic lupus erythematosus support polyclonal autoantibody production. J. Immunol. 158: 3529-3538.
52. Ryffel, B., B. D. Car, H. Gunn, et al. 1994. Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice. Am. J. Pathol. 144: 927-937.
53. Finck, B. K., B. Chan, and D. Wofsy. 1994. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J. Clin. Invest. 94: 585-591.
54. Knight, D. A., M. Ernst, G. P. Anderson, et al. 2003. The role of gp130/IL-6 cytokines in the development of pulmonary fibrosis: critical determinants of disease susceptibility and progression? Pharmacol. Ther. 99: 327-338.
55. Ha, H., M. S. Kim, J. Park, et al. 2006. Mycophenolic acid inhibits mesangial cell activation through p38 MAPK inhibition. Life Sci. 79: 1561-1567.
56. Park, J., H. Ha, J. Seo, et al. 2004. Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogen-activated protein kinase activation in rat vascular smooth muscle cells. Am. J. Transplant. 4: 1982-1990.
57. Djamali, A., A. Vidyasagar, G. Yagci, et al. 2010. Mycophenolic acid may delay allograft fibrosis by inhibiting transforming growth factor-beta1-induced activation of Nox-2 through the nuclear factor-kappaB pathway. Transplantation 90: 387-393.